Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial (Q34433768)

2 August 2017

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial (English)

1 reference

2 August 2017

phase II clinical trial

0 references

0 references

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Andrea Vaclavkova

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Sergio Chimenti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Peter Holló

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Paul-Gunther Sator

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Michel Burcklen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Mylène Stefani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Daniele D'Ambrosio

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

English

0 references

publication date

10 August 2014

1 reference

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

9959

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

2036-2045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Psoriasis causes as much disability as other major medical diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Putting together the psoriasis puzzle: an update on developing targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

The Risk of Lymphoma in Patients with Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Fingolimod for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Sphingosine-1-phosphate signaling in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Sphingosine-1-Phosphate/Sphingosine Kinase Pathway Is Involved in Mouse Airway Hyperresponsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Fingolimod-associated macular edema: incidence, detection, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960803-5

7 January 2021

10.1016/S0140-6736(14)60803-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25127208%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference